ISM5059 dose-dependently inhibited IL-1β release in the peritonitis model. (IMAGE)
Caption
Specifically, in the in vivo peritonitis model, ISM5059 demonstrated a robust, dose-dependent inhibition of Interleukin-1β (IL-1β), a potent pro-inflammatory cytokine as a master regulator of the inflammatory response. Notably, even at the lowest tested dose of 0.3 mg/kg, IL-1β levels were nearly halved compared to the vehicle control group. This was followed by a steep, progressive reduction at higher dose levels, highlighting ISM5059‘s high potency in suppressing acute inflammatory responses.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content